Blood test plus genetic score may sharpen recurrence prediction in endometrial cancer
NCT ID NCT07681414
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This observational study looks at whether combining a blood test that detects tumor DNA (ctDNA) with a new genetic risk score can better predict if endometrial cancer will come back after surgery. Researchers will follow 52 women who had a hysterectomy for endometrial cancer, collecting blood and tumor tissue for genetic analysis. The goal is to see if this combined approach helps identify who needs more or less aggressive follow-up treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to more personalized treatment decisions for endometrial cancer, helping some patients avoid unnecessary therapy while ensuring others get the intensive care they need.
What could go wrong
This is a small observational study, not a treatment trial. The findings may not change practice without larger, randomized studies to confirm them.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AMPLIFI: Web-Based Lifestyle Program for Cancer NCT04000880
- EMBER Trial: Imlunestrant for ER+ Breast Cancer NCT04188548
- RESOLVE Trial: Letrozole/Abemaciclib for ER+ End NCT03675893
- Tulmimetostat Trial for Advanced Solid Tumors & NCT04104776
- Liquid Biopsy for Female Reproductive Cancers | NCT04817501
- INSPIRE Study: Patient Reports in Tumor Boards NCT07671937
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guizhou Provincial People's Hospital
Guiyang, Guizhou, 550002, China